Cooper Consumer Health completed the acquisition of the OTC business of Viatris for $2.17bn.

Cooper Consumer Health, an independent over-the-counter drug manufacturer, completed the acquisition of the OTC business of Viatris, an American global pharmaceutical and healthcare company, for $2.17bn. "Closing the divestiture of our OTC business is a significant milestone in the execution of our strategic plan. With all our previously announced divestitures now substantially complete, Viatris is stronger and more streamlined. We look forward to an exciting future in which we continue to build on our very strong base business and add to our innovative product pipeline to drive strong future revenue growth and positively affect even more patients' lives worldwide," Scott A. Smith, Viatris Chief Executive Officer.